Federated Hermes’s Corbus Pharmaceuticals CRBP Stock Holding History

Federated Hermes’s Portfolio CRBP Stock Details CRBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.33K	Sell	355 -658	-65%	-$6.23K	﹤0.01%	1956
2026 Q1	$9.51K	Buy	1,013 +34	+3%	+$286	﹤0.01%	1846
2025 Q4	$7.97K	Buy	979 +6	+0.6%	+$74	﹤0.01%	1854
2025 Q3	$12.3K	Sell	973 -157	-14%	-$1.49K	﹤0.01%	1859
2025 Q2	$7.8K	Buy	1,130 +1,066	+1,666%	+$7.74K	﹤0.01%	1849
2025 Q1	$340	Buy	+64	New	+$565	﹤0.01%	2032
2022 Q2	–	Sell	-52	Closed	-$1K	–	2169
2022 Q1	$1K	Sell	52 -7	-12%	-$93	﹤0.01%	2072
2021 Q4	$1K	Hold	59	–	–	﹤0.01%	2101
2021 Q3	$2K	Buy	+59	New	+$2.33K	﹤0.01%	2089
2019 Q3	–	Sell	-4	Closed	-$1K	–	2219
2019 Q2	$1K	Sell	4 -23	-85%	-$4.92K	﹤0.01%	2105
2019 Q1	$6K	Buy	+27	New	+$5.96K	﹤0.01%	1947

Other funds holding CRBP

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

JHC

Jones Hill Capital New York $470M AUM

Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Federated Hermes's CRBP Position: Q2 2026 in Review

Federated Hermes reduced its Corbus Pharmaceuticals (CRBP) stake by 65% in Q2 2026, selling an estimated $6.23K and leaving 355 shares worth $3.33K. The position accounts for ﹤0.01% of the portfolio, ranked #1956.

Federated Hermes first reported a position in CRBP in Q1 2019 and has held it in 11 quarters since. The position peaked at $12.3K in Q3 2025. 107 funds tracked by Wall St. Rank hold CRBP as of Q2 2026.

Federated Hermes held 355 shares of Corbus Pharmaceuticals worth $3.33K as of Q2 2026.
Federated Hermes sold 658 Corbus Pharmaceuticals shares in Q2 2026, an estimated $6.23K.
Corbus Pharmaceuticals made up ﹤0.01% of Federated Hermes's portfolio in Q2 2026, its #1956 holding.
Federated Hermes first reported a position in Corbus Pharmaceuticals in Q1 2019 and has held it in 11 quarters since.
Federated Hermes's Corbus Pharmaceuticals position peaked at $12.3K in Q3 2025.
107 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q2 2026.

Based on Federated Hermes's 13F filing for Q2 2026, filed 12 Aug 2026.